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Abstract
Background
Prior studies have shown that AHRR (cg05575921) hypomethylation may be a marker of
smoking, lung cancer risk and potentially lung cancer survival (in some lung cancer sub-
types). It is unknown if AHRR (cg05575921) hypomethylation is associated with reduced
survival among lung cancer patients.
Methods
In bisulfite treated leukocyte DNA from 465 lung cancer patients from the Copenhagen pro-
spective lung cancer study, we measured AHRR (cg05575921) methylation. 380 died during
max follow-up of 4.4 years. Cox proportional hazard models were used to analyze survival
as a function of AHRR (cg05575921) methylation.
Results
We observed the expected inverse correlation between cumulative smoking and AHRR
methylation, as methylation (%) decreased (Coefficient -0.03; 95% confidence interval,
-0.04- -0.02, p = 8.6x10-15) for every pack-year. Cumulative smoking > 60 pack-years was
associated with reduced survival (hazard ratio and 95% confidence interval 1.48; 1.05–
2.09), however, AHRR (cg05575921) methylation was not associated with survival when
adjusted for sex, body mass index, smoking status, ethnicity, performance status, TNM
Classification, and histology type of lung cancer.
Conclusion
AHRR (cg05575921) methylation is linked to smoking but does not provide independent
prognostic information in lung cancer patients.
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Introduction
Lung cancer is the leading cause of cancer-related death worldwide [1]. The overall 5-year sur-
vival of lung cancer patients remains below 20% [2–3], mainly because tumors are diagnosed
at late stages [4]. Patients with advanced stage lung cancer are often treated with systemic che-
motherapy or immunotherapy [5] with a limited effect on the prognosis. Introduction of med-
ical therapies targeted to specific oncogenic pathways might have the potential to improve
survival for a subset of these patients [6]. However, biomarkers for identification of patients
that specifically benefits from therapy are needed.
Alteration in DNA methylation is an epigenetic modification that are common in human
malignancies [7]. Tobacco smoke alter DNA methylation and thereby influence disease
through complex mechanisms [8–9]. Altered DNA methylation is caused by tobacco smoking
with hypomethylation at cg05575921 located at the third intron of the aryl-hydrocarbon recep-
tor repressor (AHRR) [10–18]. In the general population, AHRR (cg05575921) hypomethyla-
tion of leukocyte DNA is associated with both former and current smoking status, daily
cigarette consumption, cumulative smoking and smoking duration in both former and current
smokers, and time since quitting in former smokers [19]. This suggests that blood based
AHRR (cg05575921) methylation extent can be used as an objective measure of long-term
smoking exposure.
Tobacco smoking is a prognostic marker among lung cancer patients overall [20], and after
treatment with EGFR-tyrosine kinase inhibitors [21]. Importantly, AHRR (cg05575921) meth-
ylation extent has been linked to lung cancer risk [15,17,19], and seems to be a more accurate
risk estimator of lung cancer than self-reported smoking [19]. Additionally, DNA methylation
plays a role in lung tumor initiation and progression [22–23]. It is unclear if AHRR methyla-
tion in itself is a cause of increased lung cancer risk. However, hypomethylation of AHRR has
been associated with higher AHRR expression in monocytes [24], lymphoblasts and pulmo-
nary macrophages [25], entailing decreased capability to metabolize and remove harmful
agents such as polycyclic aromatic hydrocarbons, that are contained in tobacco smoke, poten-
tially leading to development of tobacco-related lung damage.
We hypothesized that AHRR (cg05575921) hypomethylation, as a strong biomarker of
long-term smoking behavior, offers additional information beyond that offered by self-
reported smoking to identify lung cancer patients that specifically benefits from therapy. Thus,
we examined the association between AHRR (cg05575921) hypomethylation in bisulfite
treated leukocyte DNA and survival among lung cancer patients from the Lung Cancer Study
(LUCAS), also referred to as the Copenhagen study [26].
Materials and methods
Study cohort
465 consecutive individuals of the Copenhagen Study [26] who had lung cancer diagnosed at
Department of Respiratory Medicine, Bispebjerg University Hospital in Denmark between
February 2012 and December 2013. Individuals were excluded if ECOG performance status
was above 3 at first assessment by the oncologist. Cancer diagnose was cytologically or histo-
logically verified, and staged according to the TNM Classification of Malignant Tumors
(TNM).
At first assessment, individuals were asked about smoking status. Former smoking was
defined as no smoking within last 6 months. Smoking status included number of daily con-
sumed cigarettes, cheroots, cigars or pipes, age at smoking initiation and cessation. Pack-years
was consumption of 20 cigarettes or equivalent per day for 1 year. Body mass index (BMI) was
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calculated as measured weight in kilos divided by measured height in meters squared, perfor-
mance status was assessed according to ECOG classification, and a blood sample were drawn.
The study was approved by Herlev and Gentofte Hospital, the Danish Data Inspection
Agency (KF100.2039/91), and was conducted according to the Declaration of Helsinki. Writ-
ten informed consent was obtained from all participants.
AHRR hypomethylation
The AHRR (cg05575921) methylation extent was measured in duplicate samples using a Taq-
man assay developed in our own laboratory, and validated against results from pyrosequen-
cing. Bisulphite treated leucocyte DNA drawn from peripheral blood, was amplified using
forward and reverse PCR primers, which were designed to bind to DNA around the
cg05575921 site on sequences without genetic or possible CpG methylation variation. Details
of the AHRR methylation measurements have been published previously [19].
Survival
Date of death was found by linkage with the Danish Civil Registration System until January
2017. There was no loss to follow-up. The underlying cause of death until March 2017 were
obtained from the Danish Register of Causes of Death.
Statistical analysis
We used STATA/SE 15.1. All 465 individuals were categorized into ranked quantiles of AHRR
(cg05575921) methylation extent (%) with the highest methylation quantile defined as the ref-
erence category, presumably representing individuals least exposed to smoking. We showed
data in quantiles for simple illustrative presentation of the results; however, analyses on AHRR
(cg05575921) methylation extent (%) categorized into deciles and on a continuous scale are
also shown. We used Kruskal Wallis test and Pearsons X2-test to test for trend of AHRR meth-
ylation through all included variables.
Individual follow-up time began at baseline, which was defined as the date of lung cancer
diagnosis by biopsy, and ended the day of death or 31 January 2017. Minimum, median and
maximum follow-up time were 11 days, 332 days, and 4.4 years for all-cause mortality, giving a
total of 688.495 person-years and 380 deaths (81.7%).
Cox proportional hazard regression model using length of follow-up as the time metric esti-
mated hazard ratios (HRs) and 95% confidence intervals (95% CI) for the association between
AHRR (cg05575921) methylation (%) and survival in four steps with increasing level of adjust-
ment for potential a priori selected confounders. 1) a crude model, 2) a model adjusted for age
at lung cancer diagnosis and sex 3) a multivariable model additionally adjusted for body mass
index (kg/m2) (BMI), ethnicity (Europeans/others), Classification of Malignant Tumors
(TNM) (Stage I-IIII), histology of lung cancer (small cell lung cancer, adenocarcinoma, squa-
mous-cell carcinoma, other non-small-cell lung carcinoma (NSCLC), performance status (0–
3), 4) a smoking plus model additionally adjusted for smoking status (never/former/current
smoker) and cumulative smoking (defined as 20 cigarettes/day per year, calculated from
smoking intensity (number of cigarettes a day) and smoking duration (years)). Models were
applied for the whole cohort as well as stratified by cause of death (lung cancer, cardiac death,
respiratory death or other cancer) and treatment. We performed test for trend by using the
continuous variable in the Cox model. We checked for the proportional hazards assumption
for all variables based on scaled Schoenfeld residuals. Potential interactions between AHRR
(cg05575921) methylation (per 1%) and survival were tested for by introducing interaction
terms into the Cox model, and tested by the Walds test. Survival curves were generated using
AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival
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Kaplan-Meier analysis method, and the log rank test was used to examine differences in sur-
vival between the ranked quantiles of AHRR (cg05575921) methylation.
In a sensitivity analysis, we included 461 individuals without lung cancer from the 1991–
1994 examination of the Copenhagen City Heart Study [19], a prospective cohort study of the
Danish general population (S1 Table). Individuals were selected after 1:1 matching with the
lung cancer patients on body mass index, age, cumulative smoking and sex. Individual follow-
up time for all-cause mortality began at the date of examination, and ended the day of death or
14 November 2014. We did this to assess potential interaction between AHRR (cg05575921)
methylation and lung cancer status on survival. Potential interactions were tested for by intro-
ducing interaction terms into the Cox model, and tested by the Walds test.
To validate the methylation measurement, we used linear regression analysis to measure
expected association between cumulative smoking and AHRR (cg05575921) methylation. To
assess the expected association between all-cause mortality and cumulative smoking, treat-
ment, recurrence, ECOG performance status and TNM-status, we used the Cox model.
Results
A priori we calculated the power of the study, and the study has 80% power to detect reduced
survival of at least 6% every time AHRR (cg05575921) hypomethylation is reduced by 1%
(SD = 2.17%).
The study population consisted of 465 lung cancer cases (Table 1), slightly more women
(51.8%) than men with a median age of 68.3 years. Median of AHRR (cg05575921) methylation
was 56.0%. A majority of cases was European (97.4%), had body mass index between 18.5 and
24.9 (kg/m2), were former smokers (56.5%), TNM stage IIII (52.0%), at performance status 1
(40.0%), had adenocarcinoma (54.4%), received platinium-based chemotherapy as first onco-
logical treatment (65.2%), had one line of treatment (65.0%) and had no recurrence of their
lung cancer within the follow-up period (79.1%).
As shown previously [21] AHRR methylation extent differed with cumulative smoking; the
median methylation extent was 58.0% for pack-years< = 20 (interquartile range (IQR): 56.6–
60.2), 56.0% pack-years >20–40 (54.7–57.1) and 55.7% for pack-years >40–60 (54.6–56.6) and
55.7% for pack-years >60 (54.3–56.6) (S1 Fig); and with smoking status; never smokers 60.2%
(58.4–61.8), former smokers 56.6% (55.7–57.8) and current smokers 55.1% (54.1–56.0) (S2
Fig). Further, the expected inverse correlation between cumulative smoking and AHRR meth-
ylation was observed, as methylation (%) decreased (coefficient -0.03; 95 CI, -0.04- -0.02,
p = 8.6x10-15) for every pack-year) and (coefficient -0.06 (-0.07- -0.04), 7.3x10-10) for every
smoking-year, in the crude model (Table 2).
Compared to individuals with cumulative smoking�20 pack-years, reduced survival
seemed stronger among individuals with cumulative smoking >60 pack-years (HR: 1.48; 95%
CI: 1.05–2.09) (Table 3). We found association with poorer performance status (p-trend =
1.1x10-31) and advanced TNM-status (p-trend = 2.2x10-32) and reduced survival (S3 Table).
For performance status, which displayed the strongest association with reduced survival, the
smoking plus adjusted hazard ratio for the poorest versus the best performance status was 7.48
(95% CI; 4.67–12.00).
Compared to patients in the highest AHRR methylation quartile there was no association
with survival for individuals in the lowest quartile (1.00; 0.75–1.32) or the lowest decile (1.18;
0.67–2.09) versus the highest quartile or decile. In continuous models using AHRR methyla-
tion (per 1%) as exposure, results were similar (Table 4 and S6 Table).
In addition, we observed no associations after stratification by specific causes of death; lung
cancer, cardiac disease, respiratory disease or other cancer (S7 Table).
AHRR (cg05575921) methylation extent of leukocyte DNA and lung cancer survival
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Table 1. Baseline characteristics of 465 patients with lung cancer by leukocyte DNA methylation of AHRR (cg05575921), quantiles.
Total Leukocyte DNA methylation of AHRR (cg05575921), quantiles
1st (highest)
57.4–63.4%
2nd
56.0–57.4%
3rd
54.9–56.0%
4th (lowest)
50.0–54.9%
p-valuea
Total (%) 465 123 (26.5) 109 (23.4) 120 (25.8) 113 (24.3) -
Age years 68.3 (62.7–74.7) 70.2 (64.9–77.0) 67.7 (63.2–74.7) 67.9 (61.3–73.0) 66.9 (59.7–73.7) 0.05
AHRR (cg05575921) methylation extent (%) 56.0 (54.9–57.4) 58.6 (58.0–60.0) 56.6 (56.4–56.9) 55.5 (55.1–55.8) 54.0 (53.3–54.3) NA
Sex
Men 224 (48.2) 52 (42.3) 57 (52.3) 62 (51.7) 53 (46.9)
Women 241 (51.8) 71 (57.7) 52 (47.7) 58 (48.3) 60 (53.1) 0.37
Ethnicity,
European 453 (97.4) 118 (95.9) 107 (98.2) 116 (96.7) 112(93.8)
Others 12 (2.6) 5 (4.1) 2 (1.8) 4 (3.3) 1 (0.9) 0.41
Body mass index (kg/m2)
<18.5 50 (10.8) 2 (1.6) 12 (11.0) 18 (15.0) 18 (15.9)
18.5–24.9 223 (48.0) 62 (50.4) 49 (45.0) 53 (44.2) 59 (52.2)
25.0–29.9 111 (23.9) 31 (25.2) 29 (26.6) 32 (26.7) 19 (16.8)
�30.0 37 (8.0) 16 (13.0) 7 (6.4) 8 (6.7) 6 (5.3)
Missing, n (%) 44 (9.4) 12 (9.8) 12 (11.0) 9 (7.5) 11 (9.7) 0.004
Smoking status
Never 28 (6.0) 24 (19.5) 1 (0.9) 2 (1.7) 1 (0.9)
Former (>6 months ago) 262 (56.5) 87 (70.7) 79 (72.5) 56 (46.7) 40 (35.4)
Current 174 (37.5) 11 (8.9) 29 (26.6) 62 (51.6) 72 (64.6)
Missing, n (%) 1 (0.0) 1 (0.8) 0 (0.0) 0 (0.0) 0 (0.0) 2.4x10-25
Cumulative smokingb, pack-years 40.0 (24. 0–51.4) 22.7 (2.5–40) 41.0 (28–54.2) 43.4 (29.5–53.0) 44.5 (32.4–56.3) 0.0001
Missing 10 (2.2) 5 (4.1) 2 (1.8) 2 (1.7) 1 (0.9)
Smoking duration, years 47.0 (40.0–54.0) 41.5 (27.5–51.2) 48 (42.0–54.0) 49.0 (41.0–56.0) 49.0 (43.3–55.0) 0.0002
Missing, n (%) 100 (21.5) 14 (11.4) 29 (26.7) 31 (25.8) 26 (23.0)
Time since smoking cessation, years 3.3 (0.8–12.4) 10.2 (3.4–18.4) 2.0 (0.6–8.9) 1.0(0.7–4.1) 1.0(0.7–6.1) 0.0001
Missing 35 (7.5) 10 (8.1) 15 (13.7) 8 (6.7) 4 (3.5)
TNM Classification of Malignant Tumours (TNM)
Stage Ia-b 26 (5.6) 3 (2.5) 8 (7.3) 6 (5.0) 9 (8.0)
Stage IIa-b 33 (7.1) 6 (4.9) 11 (10.1) 8 (6.7) 8 (7.1)
Stage IIIa-b 163 (35.1) 35 (28.7) 44 (40.4) 47 (39.2) 40 (35.4)
Stage IIII 242 (52.0) 78 (63.9) 49 (45.0) 59 (49.2) 56 (49.6)
Missing, n (%) 1 (0.2) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0.16
Performance status
0 158 (34.0) 45 (36.6) 44 (40.4) 35 (29.2) 34 (30.1)
1 186 (40.0) 50 (40.7) 43 (39.4) 51 (42.5) 42 (37.2)
2 81 (17.4) 16 (13.0) 16 (14.7) 27 (22.5) 22 (19.5)
3 35 (7.5) 10 (8.1) 6 (5.5) 6 (5.0) 13 (11.5)
Missing, n (%) 5 (1.1) 2 (1.6) 0 (0.0) 1 (0.8) 2 (1.8) 0.26
Histology
Small cell lung cancer 78 (16.8) 11 (8.9) 15 (13.8) 25 (20.8) 27 (23.9)
NSCLC, adenocarcinoma 253 (54.4) 76 (61.8) 58 (53.2) 63 (52.5) 56 (49.6)
NSCLC, squamous carcinoma 102 (21.9) 25 (20.3) 29 (26.6) 23 (19.2) 25 (22.1)
NSCLC, other 32 (6.9) 11 (8.9) 7 (6.4) 9 (7.5) 5 (4.4) 0.09
First treatment for lung cancerc
Platinum-based therapy 303 (65.2) 83 (67.5) 83 (76.2) 81 (67.5) 56 (49.6)
(Continued)
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In order to further investigate the lack of association between AHRR methylation extent
and reduced survival in lung cancer patients, we also analyzed the association in individuals
without lung cancer (Table 5). After multivariable adjustments including age, sex, ethnicity,
body mass index and cumulative smoking, hazard ratio for death was 1.49 (95% CI; 1.16–1.93)
for the lowest quantile of AHRR methylation extent versus the highest. There was no interac-
tion between lung cancer status and AHRR methylation with survival.
Discussion
In this study of 465 lung cancer cases, we observed no association between AHRR
(cg05575921) methylation and survival.
With 81.7% mortality after a median follow up time of 332 days, the overall prognosis for
the patient was as expected for lung cancer [27]. Further, since reduced survival was strongly
associated with high cumulative tobacco consumption, poor performance status, and with
advanced TNM we expect data to be in line with the usual finding. Also, the measurement of
AHRR methylation was precise enough to pick up the expected association with cumulative
smoking. Therefore, since both exposure and outcome variables were presumably accurately
measured and we observed the expected association between AHRR methylation and reduced
Table 1. (Continued)
Total Leukocyte DNA methylation of AHRR (cg05575921), quantiles
1st (highest)
57.4–63.4%
2nd
56.0–57.4%
3rd
54.9–56.0%
4th (lowest)
50.0–54.9%
p-valuea
Therapy,combinationd 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.9)
Therapy,monotherapyd 3 (0.7) 2 (0.0) 1 (0.9) 0 (0.0) 0 (0.0)
Targeted therapye 3 (0.7) 2 (1.6) 0 (0.0) 0 (0.0) 1 (0.9)
Immunotherapy 4 (0.9) 2 (1.6) 0 (0.0) 1 (0.8) 1 (0.9)
No oncological treatmentf 151 (32.5) 34 (27.6) 25 (22.9) 38 (31.7) 54 (47.8) 0.01
Recurrence of lung cancerg
No 368 (79.1) 100 (81.3) 81 (74.3) 92 (76.7) 95 (84.1)
Yes 97 (20.9) 23 (18.7) 28 (25.7) 28 (23.3) 18 (15.9) 0.26
<3 months of treatment start 11 (11.3) 3 (13.0) 4 (14.3) 2 (7.1) 2 (11.1)
>3 months of treatment start 86 (88.7) 20 (87.0) 24 (85.7) 26 (92.9) 16 (88.9) 0.85
Total lines of treatment
1 204 (65.0) 62 (69.7) 50 (59.5) 53 (64.6) 39 (66.1)
2 75 (23.9) 14 (15.7) 26 (31.0) 19 (23.2) 16 (27.1)
3 27 (8.6) 9 (10.1) 7 (8.3) 9 (11.0) 2 (3.4)
4 5 (1.6) 2 (2.3) 1 (1.2) 1 (1.22) 1 (1.7)
5 2 (0.6) 1 (1.1) 0 (0.0) 0 (0.0) 1 (1.7)
6 1 (0.3) 1 (1.1) 0 (0.0) 0 (0.0) 0 (0.0) 0.59
Values are median (p25 p75) for continuous values and number (frequencies) for categorical values.
AHRR, Aryl-hydrocarbon receptor repressor. NSCLC, non-small-cell lung carcinoma.
a p-values (two-sided) were calculated with Kruskal Wallis test for continuous values and Pearsons X2-test for categorical values.
b Pack-years corresponding to the consumption of 20 cigarettes per day for 1 year.
c First oncological treatment for lung cancer (after surgery). Surgery are performed at patients with TMN stage I and II and <5% of patients with TMN IIIa.
d No platin.
e ALKI/EGFR-mutation.
f Other than surgery.
g Within the follow-up period of the study.
https://doi.org/10.1371/journal.pone.0211745.t001
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survival among individuals without lung cancer, we assume that the lack of association is cor-
rect, and not caused by measurement or registration errors.
We speculate that the lack of association could be due to individual threshold phenomena,
where smoking can only reduce AHRR methylation to a certain low level in each individual,
and the level of this threshold is not determined by factors associated with reduced survival.
Having reached this threshold, more intensive smoking reduces survival, but will not reduce
methylation further as suggested by the very narrow range of AHRR methylation in the lung
cancer patients compared with the matched individuals from the general population without
lung cancer. Further, since AHRR methylation only reverts very slowly over decades after
smoking cessation [6], the prognostic benefit from quitting within years before blood sam-
pling, cannot be monitored by measuring AHRR methylation, especially in cohorts with poor
short-term prognosis, i.e. lung cancer patients. Further, we found that AHRR hypomethylation
behaves different on reduced survival in lung cancer patients than in individuals without lung
cancer. Along with prior studies [15,17,19] showing association between AHRR hypomethyla-
tion and increased lung cancer risk, these findings suggest that smoking-associated methyla-
tion changes are more involved in initiation than progression of lung cancer.
Table 2. Association between AHRR (cg05575921) methylation extent, smoking status, cumulative smoking (pack-years), smoking duration and cessation (years)
among 465 patients with lung cancer.
Coefficient (95% CI) Age and sex-adjusted coefficient (95% CI) Multivariable adjusted a
coefficient (95% CI)
Smoking status
Never 1.00 1.00 1.00
Former -3.18 (-3.87- -2.49) -3.14 (-3.84- -2.45) -3.09 (-3.86- -2.33)
Current -4.91 (-5.62- -4.20) -4.87 (-5.58- -4.15) -4.66 (-5.4- -3.86)
Cumulative smoking, pack-years -0.03 (-0.04- -0.02) -0.03 (-0.04 - -0.02) -0.03 (-0.03- -0.02),
p-value 8.6x10-15 2.6x10-15 1.8x10-11
Smoking duration, years -0.06 (-0.07- -0.04) -0.09 (-0.11- -0.07) -0.08 (-0.10- -0.06)
p-value 7.3x10-10 1.4x10-19 3.4x10-15
Time since smoking cessation, years 0.07 (0.06–0.09) 0.07 (0.05–0.09) 0.09 (0.07–0.11)
p-value 7.3x10-13 1.7x10-11 2.3x10-18
AHRR, Aryl-hydrocarbon receptor repressor. CI, confidence interval.
A priori potential confounders were selected, and included in models 1) A crude model, 2) A model, additionally adjusted for age at lung cancer diagnosis and sex. 3) aA
model, additionally adjusted for body mass index (kg/m2), ethnicity (European/others), TNM Classification of Malignant Tumors (TNM) (Stage I-IIII), histology of
lung cancer (small cell lung cancer, adenocarcinoma, squamous-cell carcinoma, other non-small-cell lung carcinoma (NSCLC), performance status (0–3). . .
https://doi.org/10.1371/journal.pone.0211745.t002
Table 3. Association between cumulative smoking (pack-years) and reduced survival (from all-cause mortality) among 465 patients with lung cancer.
Cumulative smoking, pack-years, categorical variable Crude hazard ratio for death (95% CI) Age and sex-adjusted
hazard ratio for death (95% CI)
Multivariable adjusted a
hazard ratio for death (95% CI)
�20 1.00 1.00 1.00
20–40 1.20 (0.89–1.60) 1.28 (0.94–1.71) 1.54 (1.09–2.13)
40–60 1.04 (0.78–1.39) 1.02 (0.78–1.36) 1.06 (0.75–1.49)
>60 1.48 (1.05–2.09) 1.41 (1.00–1.99) 1.29 (0.88–1.92)
CI, confidence interval.
A priori potential confounders were selected, and included in models 1) A crude model, 2) A model, additionally adjusted for age at lung cancer diagnosis and sex. 3) aA
model, additionally adjusted for body mass index (kg/m2), ethnicity (European/others), TNM Classification of Malignant Tumors (TNM) (Stage I-IIII), histology of
lung cancer (small cell lung cancer, adenocarcinoma, squamous-cell carcinoma, other non-small-cell lung carcinoma (NSCLC), performance status (0–3).
https://doi.org/10.1371/journal.pone.0211745.t003
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Although AHRR methylation might be useful in assessing lung cancer risk in a population
of smokers [19], our results suggest that it cannot identify lung cancer patients with poor prog-
nosis independently of other commonly used prognostic factors.
Strengths of this study was the prospective design with detailed information on many
covariates, complete follow-up, and no misclassification of vital status in Denmark. Lung can-
cer diagnosis was based on pathology confirmation by a trained pathologist.
Some limitations must, however, be acknowledged. 16 (3,4%) patients had>30 days from
date of blood sample and date of diagnosis. However, these represented a non-differential sam-
ple according to reduced survival. Possible changes in AHRR methylation during follow-up
Table 4. Association between AHRR (cg05575921) methylation extent (%) and reduced survival (from all-cause mortality) among 465 patients with lung cancer.
Crude hazard ratio
for death (95% CI)
Age and sex-adjusted hazard
ratio for death (95% CI)
Multivariable adjusted ahazard
ratio for death (95% CI)
Smoking plus adjusted bhazard
ratio for death (95% CI)
AHRR (cg05575921) methylation
extent (%), categorical variable
n = 465 n = 465 n = 417 n = 410
57.4–63.4 (Highest) 1.00 1.00 1.00 1.00
56.0–57.4 0.87 (0.65–1.16) 0.84 (0.63–1.12) 1.01 (0.74–1.39) 0.86 (0.61–1.22)
54.9–56.0 1.03 (0.78–1.35) 1.02 (0.77–1.35) 1.09 (0.80–1.49) 0.92 (0.65–1.31)
50.0–54.9 (lowest) 1.00 (0.75–1.32) 0.99 (0.75–1.32) 1.16 (0.84–1.61) 1.03 (0.70–1.52)
p-trend 0.46
AHRR (cg05575921) methylation
extent (%), continuous variable
1.00 (0.95–1.04) 1.00 (0.95–1.05) 0.97 (0.92–1.02) 0.98 (0.91–1.05)
p-trend 0.40
AHRR, Aryl-hydrocarbon receptor repressor. CI, confidence interval.
A priori potential confounders were selected, and included in models 1) A crude model, 2) A model, additionally adjusted for age at lung cancer diagnosis and sex. 3) aA
model, additionally adjusted for body mass index (kg/m2), ethnicity (European/others), TNM Classification of Malignant Tumors (TNM) (Stage I-IIII), histology of
lung cancer (small cell lung cancer, adenocarcinoma, squamous-cell carcinoma, other non-small-cell lung carcinoma (NSCLC), performance status (0–3), 4) bA model
additionally adjusted for smoking status (never/former/current smoker) and cumulative smoking (defined as 20 cigarettes/day per year, calculated from smoking
intensity (number of cigarettes a day) and smoking duration (years).
https://doi.org/10.1371/journal.pone.0211745.t004
Table 5. Association between AHRR (cg05575921) methylation extent in quantiles (%) and reduced survival (from all-cause mortality) in 461 matched individuals
without lung cancer.
AHRR (cg05575921) methylation
extent (%), categorical variable
Number Crude hazard
ratio for death
(95% CI)
Age and sex-adjusted hazard
ratio for death (95% CI)
Multivariable adjusted ahazard
ratio for death (95% CI)
Smoking plus adjusted
bhazard ratio for death (95%
CI)
57.4–63.4 (Highest) 131 1.00 1.00 1.00 1.00
56.0–57.4 11 0.92 (0.45–1.89) 1.61 (0.78–3.33) 1.60 (0.77–3.32) 1.60 (0.77–3.32)
54.9–56.0 36 1.12 (0.74–1.68) 1.27 (0.84–1.91) 1.19 (0.78–1.82) 1.15 (0.75–1.76)
50.0–54.9 (Lowest) 283 1.10 (0.87–1.40) 1.58 (1.24–2.01) 1.59 (1.24–2.04) 1.49 (1.16–1.93)
p-trend 0.003
p-interaction� 0.96 0.89 0.99 0.87
AHRR, Aryl-hydrocarbon receptor repressor, CI, confidence interval.
A priori potential confounders available for populations without lung cancer were selected, and included in models 1) A crude model, 2) A model, additionally adjusted
for age and sex. 3) aA model, additionally adjusted for body mass index (kg/m2), ethnicity (European/others) 4) bA model additionally adjusted for cumulative smoking
(defined as 20 cigarettes/day per year, calculated from smoking intensity (number of cigarettes a day) and smoking duration (years).
� Results from the interaction test, including an introducing of AHRR (cg05575921) methylation extent X lung cancer status interaction term into the Cox model, to
compare hazard ratios in Table 4 with hazard ratios in Table 5.
https://doi.org/10.1371/journal.pone.0211745.t005
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could not been taken into account. Also, we do not have information on the exposure of pas-
sive smoking. This would have been relevant to include in our analyses since AHRR hypo-
methylation has also been found in those exposed to passive smoke [28]. Since it is also
associated with reduced survival [29], inclusion of passive smoking in the analyses would prob-
ably have weakened the association between smoking and AHRR hypomethylation, but likely
not the association between AHRR hypomethylation and reduced survival.
Conclusion
AHRR (cg05575921) methylation cannot be used to predict smoking mediated reduced sur-
vival in lung cancer patients.
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patients with lung cancer. CI, confidence interval.
a Include platinum-based chemotherapy, combination and monotherapy, targeted therapy
(ALKi/EGFR-mutation), immunotherapy, no oncological treatment other than surgery.
b Within the follow-up period of the study.
A priori potential confounders were selected, and included in models 1) A crude model, 2) A
model, additionally adjusted for age at lung cancer diagnosis and sex. 3) cA model, additionally
adjusted for body mass index (kg/m2), ethnicity (European/others), TNM Classification of
Malignant Tumors (TNM) (Stage I-IIII), histology of lung cancer (small cell lung cancer, ade-
nocarcinoma, squamous-cell carcinoma, other NSCLC), ECOG performance status (0–3), 4)
dA model additionally adjusted for smoking status (never/former/current smoker) and cumu-
lative smoking (defined as 20 cigarettes/day per year, calculated from smoking intensity (num-
ber of cigarettes a day) and smoking duration (years).
(DOCX)
S5 Table. Association between AHRR (cg05575921) methylation extent and reduced sur-
vival (from all-cause mortality) by oncological treatment for lung cancer, recurrence of
lung cancer and total lines of treatment among 465 patients with lung cancer. AHRR, Aryl-
hydrocarbon receptor repressor CI, confidence interval.
a Include platinium-based chemotherapy, combination and monotherapy, targeted therapy
(ALKI/EGFR-mutation), immunotherapy, no oncological treatment other than surgery.
A priori potential confounders were selected, and included in models 1) A crude model, 2) A
model, additionally adjusted for age at lung cancer diagnosis and sex. 3) bA model, additionally
adjusted for body mass index (kg/m2), ethnicity (European/others), TNM Classification of
Malignant Tumors (TNM) (Stage I-IIII), histology of lung cancer (small cell lung cancer, ade-
nocarcinoma, squamous-cell carcinoma, other non-small-cell lung carcinoma (NSCLC),
ECOG performance status (0–3), 4) cA model additionally adjusted for smoking status (never/
former/current smoker) and cumulative smoking (defined as 20 cigarettes/day per year, calcu-
lated from smoking intensity (number of cigarettes a day) and smoking duration (years).
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S6 Table. Association between AHRR (cg05575921) methylation extent in deciles (%) and
reduced survival (from all-cause mortality) among 465 patients with lung cancer. AHRR,
Aryl-hydrocarbon receptor repressor, CI, confidence interval.
A priori potential confounders were selected, and included in models 1) A crude model, 2) A
model, additionally adjusted for age at lung cancer diagnosis and sex. 3) aA model, additionally
adjusted for body mass index (kg/m2), ethnicity (European/others), TNM Classification of
Malignant Tumors (TNM) (Stage I-IIII), histology of lung cancer (small cell lung cancer, ade-
nocarcinoma, squamous-cell carcinoma, other non-small-cell lung carcinoma (NSCLC),
ECOG performance status (0–3), 4) bA model additionally adjusted for smoking status (never/
former/current smoker) and cumulative smoking (defined as 20 cigarettes/day per year, calcu-
lated from smoking intensity (number of cigarettes a day) and smoking duration (years).
(DOCX)
S7 Table. Association between by AHRR (cg05575921) methylation extent and reduced
survival by registered cause of deatha (lung cancer, cardiac disease, respiratory disease and
other cancers) among 385 patients with lung cancer. AHRR, Aryl-hydrocarbon receptor
repressor CI, confidence interval.
a One individual is registered with up till nine causes of death, and might be included in ana-
lyzes with several causes of death.
A priori potential confounders were selected, and included in models 1) A crude model, 2) A
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model, adjusted for age at lung cancer diagnosis and sex. 3) bA model, additionally adjusted
for body mass index (kg/m2), ethnicity (European/others), TNM Classification of Malignant
Tumors (TNM) (Stage I-IIII), histology of lung cancer (small cell lung cancer, adenocarci-
noma, squamous-cell carcinoma, other non-small-cell lung carcinoma (NSCLC), ECOG per-
formance status (0–3) 4) cA model additionally adjusted for smoking status (never/former/
current smoker) and cumulative smoking (defined as 20 cigarettes/day per year, calculated
from smoking intensity (number of cigarettes a day) and smoking duration (years).
(DOCX)
S1 Fig. Cumulative smoking as a function of AHRR (cg05575921) methylation extent (%)
among former and current smokers among patients with lung cancer. Values are median
(p25 p75). AHRR, Aryl-hydrocarbon receptor repressor
p-values (two-sided) were calculated with Pearsons X2-test for categorical values.
(TIF)
S2 Fig. Smoking status as a function of AHRR (cg05575921) methylation extent (%) among
patients with lung cancer. Values are median (p25 p75).
AHRR, Aryl-hydrocarbon receptor repressor
p-values (two-sided) were calculated with Pearsons X2-test for categorical values.
(TIF)
S3 Fig. Kaplan-Meier plot of all-cause survival by AHRR (cg05575921) methylation extent
in quantiles (%) among 465 patients with lung cancer. AHRR, Aryl-hydrocarbon receptor
repressor
1st: Highest quantiles of AHRR (cg05575921) methylation extent.
4st: Lowest quantiles of AHRR (cg05575921) methylation extent.
(TIF)
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